Established 1999
123jump.com - U.S. Financial Information Archive: 90,000 Annual and 10-K reports – 20,000 Global news stories - 3,500 IPO reports - 1,700 - Earnings Calls – 320 Fund Interviews – 10-year Annual earnings on 4,500 stocks – 20 Quarterly earnings on 3,600 stocks – 1,800 IPO prospectuses – 1,200 Economic data releases
     
   
 
  Quotes Find Symbol:
 Company Links
4001 Miranda Avenue
Palo Alto, CA 94304
USA
+1-650-812-8700
http://www.affymax.com
 Management    Source: Company documents
Name : Arlene M. Morris
Title : President, Chief Executive Officer, Director
Since: 2003
Name : Paul B. Cleveland
Title : Chief Financial Officer, Executive Vice President - Corporate Development
Since: 01/2006
Name : Steven Love
Title : Vice President - Finance
Since: 08/21/2007
Name : Kay Slocum
Title : Senior Vice President - Human Resources
Since: 2006
Name : Grace U. Shin
Title : Vice President - Legal Affairs, Corporate Counsel
Since: 10/25/2006
Name : Douglas L. Cole
Title : Vice President - Development
Since: 2004
Name : Christine Conroy
Title : Vice President - Regulatory Affairs and Good Clinical Practice Compliance
Since: 07/31/2007
Name : Tracy J. Dunn
Title : Vice President - Intellectual Property and Legal Affairs
Since: 2002
Name : Peter R. Young
Title : Vice President - Research
Since: 07/24/2007
Name : Christopher Dammann
Title : Vice President - Business Developmen
Since: 01/2006
Name : Anne-Marie Duliege, M.D., M.S.
Title : Chief Medical Officer
Since: 07/2007
 Earnings Calls
Earnings Release Dates : 9th May 2008
Audio
 Annual Reports
• Annual Report 2006
 Quarterly Earnings - AFFY
Sequential Earnings Growth | Quarterly Earnings by Year | Quarterly Earnings Growth by Year

Source: Company filings    Q1:March  Q2:June  Q3:September  Q4:December
 Annual Earnings - AFFY
Annual earnings growth

Diluted EPS Excluding Extraordinary Items     Source: Company filings
 IPO Reports:
Affymax, Inc.
The Company’s lead product candidate, Hematide, is designed to treat anemia associated with chronic kidney disease and cancer. Hematide is a synthetic peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate production of red blood cells. Hematide is designed to be longer acting than currently marketed ESAs, and therefore has the potential to offer both better care for patients and reduced cost and complexity for healthcare providers.
More...




   
© 1999-2008 123jump.com. All rights reserved